QINLOCK Drug Patent Profile
✉ Email this page to a colleague
When do Qinlock patents expire, and when can generic versions of Qinlock launch?
Qinlock is a drug marketed by Deciphera Pharms and is included in one NDA. There are twenty-six patents protecting this drug.
This drug has eighty-four patent family members in twenty-two countries.
The generic ingredient in QINLOCK is ripretinib. One supplier is listed for this compound. Additional details are available on the ripretinib profile page.
DrugPatentWatch® Generic Entry Outlook for Qinlock
Qinlock was eligible for patent challenges on May 15, 2024.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 30, 2040. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for QINLOCK
| International Patents: | 84 |
| US Patents: | 26 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 33 |
| Clinical Trials: | 1 |
| Patent Applications: | 43 |
| Drug Prices: | Drug price information for QINLOCK |
| What excipients (inactive ingredients) are in QINLOCK? | QINLOCK excipients list |
| DailyMed Link: | QINLOCK at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for QINLOCK
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for QINLOCK
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Deciphera Pharmaceuticals LLC | Phase 1 |
Pharmacology for QINLOCK
Anatomical Therapeutic Chemical (ATC) Classes for QINLOCK
US Patents and Regulatory Information for QINLOCK
QINLOCK is protected by twenty-six US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of QINLOCK is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting QINLOCK
Methods of treating gastrointestinal stromal tumors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS HAVING PROGRESSED FROM A FIRST LINE ADMINISTRATION OF IMATINIB, A SECOND LINE ADMINISTRATION OF SUNITINIB, AND A THIRD LINE ADMINISTRATION OF REGORAFENIB
Amorphous kinase inhibitor formulations and methods of use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods of treating gastrointestinal stromal tumors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM PALMER-PLANTER ERYTHRODYSESTHESIA SYNDROME
Methods of treating gastrointestinal stromal tumors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM HYPERTENSION
Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-- 3-yl)-2-fluorophenyl)-3-phenylurea
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods of treating gastrointestinal stromal tumors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS BEING TREATED CONCURRENTLY WITH A CYP3A4 INHIBITOR
Methods of treating gastrointestinal stromal tumors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM GRADE 2 OR GRADE 3 MYALGIA WHILE BEING ADMINISTERED RIPRETINIB DAILY
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM A GRADE 3 ADVERSE REACTION WHILE BEING ADMINISTERED RIPRETINIB DAILY
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS PREVIOUSLY ADMINISTERED AT LEAST THREE TYROSINE KINASE INHIBITORS, WHERE ONE OF THE KINASE INHIBITORS IS IMATINIB
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM GRADE 2 OR GRADE 3 ARTHRALGIA WHILE BEING ADMINISTERED RIPRETINIB DAILY
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS HAVING PRE-EXISTING SEVERE HEPATIC IMPAIRMENT AND SUFFERING FROM AN ADVERSE EVENT WHILE BEING ADMINISTERED RIPRETINIB DAILY
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH A WILD TYPE KIT MUTATION IN PATIENTS PREVIOUSLY ADMINISTERED THREE OR MORE KINASE INHIBITORS, WHERE ONE OF THE KINASE INHIBITORS IS IMATINIB
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
FDA Regulatory Exclusivity protecting QINLOCK
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE RECEIVED PRIOR TREATMENT WITH 3 OR MORE KINASE INHIBITORS, INCLUDING IMATINIB
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for QINLOCK
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Deciphera Pharmaceuticals (Netherlands) B.V. | Qinlock | ripretinib | EMEA/H/C/005614 Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. |
Authorised | no | no | yes | 2021-11-18 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for QINLOCK
When does loss-of-exclusivity occur for QINLOCK?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 2354
Estimated Expiration: ⤷ Sign Up
Patent: 2355
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 20417282
Estimated Expiration: ⤷ Sign Up
Patent: 20419197
Estimated Expiration: ⤷ Sign Up
Patent: 23241368
Estimated Expiration: ⤷ Sign Up
Patent: 23248048
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2022013109
Estimated Expiration: ⤷ Sign Up
Patent: 2022013169
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 63051
Estimated Expiration: ⤷ Sign Up
Patent: 63053
Estimated Expiration: ⤷ Sign Up
China
Patent: 5135308
Estimated Expiration: ⤷ Sign Up
Patent: 5243681
Patent: 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物 (Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-pendant oxy-1, 2-dihydro-1, 6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea)
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 84778
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 84778
Estimated Expiration: ⤷ Sign Up
Patent: 84779
Estimated Expiration: ⤷ Sign Up
Patent: 27827
Estimated Expiration: ⤷ Sign Up
Finland
Patent: 84778
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 3864
Estimated Expiration: ⤷ Sign Up
Patent: 3866
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 23509628
Estimated Expiration: ⤷ Sign Up
Patent: 23509629
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 84778
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 22008097
Estimated Expiration: ⤷ Sign Up
Patent: 22008103
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 84778
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 84778
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 058
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 84778
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 220123057
Estimated Expiration: ⤷ Sign Up
Patent: 220123058
Patent: 1--3-페닐우레아의 조성물
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 2136257
Estimated Expiration: ⤷ Sign Up
Patent: 2136258
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering QINLOCK around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2008033999 | ⤷ Sign Up | |
| Canada | 3150433 | ⤷ Sign Up | |
| Australia | 2023248048 | Amorphous kinase inhibitor formulations and methods of use thereof | ⤷ Sign Up |
| Japan | 5265550 | ⤷ Sign Up | |
| China | 115135308 | 非晶型激酶抑制剂制剂及其使用方法 (Amorphous kinase inhibitor formulations and methods of use thereof) | ⤷ Sign Up |
| Japan | 2010503702 | ⤷ Sign Up | |
| European Patent Office | 4327827 | FORMULATIONS D'INHIBITEURS DE KINASE AMORPHE ET LEURS PROCÉDÉS D'UTILISATION (AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
